Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB

Thumbnail
View/ Open

Show full item record

Author
McCubrey, James A.
URI
http://hdl.handle.net/10342/9588
Date
2016-01-12
Citation:
APA:
McCubrey, James A.. (January 2016). Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB. Oncotarget, (7:2), p.1323-1340. Retrieved from http://hdl.handle.net/10342/9588

Display/Hide MLA, Chicago and APA citation formats.

MLA:
McCubrey, James A.. "Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB". Oncotarget. 7:2. (1323-1340.), January 2016. May 24, 2022. http://hdl.handle.net/10342/9588.
Chicago:
McCubrey, James A., "Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB," Oncotarget 7, no. 2 (January 2016), http://hdl.handle.net/10342/9588 (accessed May 24, 2022).
AMA:
McCubrey, James A.. Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB. Oncotarget. January 2016; 7(2) 1323-1340. http://hdl.handle.net/10342/9588. Accessed May 24, 2022.
Collections